Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, daltepari...
Nanjing King-Friend Biochemical Pharmaceutical reported revenue of 3.99 billion CNY for fiscal year 2025, up 1.8% from fiscal year 2024, and net income of 581.54 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 928.66 million CNY, up 4.9% from a year before. Its largest business segment, Pharmaceutical Preparations, brought in 78% of segment revenue in fiscal year 2024; Foreign was the largest region with 77%.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.